What Happened?

Shares of medical device company Integra LifeSciences (NASDAQ:IART) fell 28.5% in the morning session after the company reported weak first-quarter 2025 results, which included a significant miss on full-year EPS guidance and the next quarter's revenue outlook.

Segment results were mixed as key businesses like Neurosurgery and Tissue Technologies declined, pulled down by inventory issues and slower ordering patterns. Along with rising costs, margins and profit were dragged down as EBITDA and EPS both dropped, and cash flow was in the red. Even though management kept the full-year sales target, they had to cut their profit outlook due to tariff concerns. Overall, this quarter could have been better.

The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Integra LifeSciences? Access our full analysis report here, it’s free.

What The Market Is Telling Us

Integra LifeSciences’s shares are very volatile and have had 21 moves greater than 5% over the last year. But moves this big are rare even for Integra LifeSciences and indicate this news significantly impacted the market’s perception of the business.

The biggest move we wrote about over the last year was 2 months ago when the stock gained 13.6% on the news that the company reported strong fourth quarter 2024 results that beat analysts' EPS and EBITDA expectations.

On the other hand, its full-year revenue and EPS guidance fell short of Wall Street's estimates. The company expects continued demand for its portfolio but flagged potential headwinds, including intermittent product shipping holds. Overall, while this was a strong quarter with solid execution, cautious guidance suggests near-term uncertainty.

Integra LifeSciences is down 45.8% since the beginning of the year, and at $12.48 per share, it is trading 60.8% below its 52-week high of $31.86 from June 2024. Investors who bought $1,000 worth of Integra LifeSciences’s shares 5 years ago would now be looking at an investment worth $240.51.

Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.

View Comments